-
Blosozumab binds SOST, a
negative regulator of
osteoblast activity.
Blocking SOST
activity can lead to
increased bone density.
Blosozaumab has been studied...
- INN) Blis-To-Sol (Oakhurst Company)
Blocadren (Merck)
blonanserin (INN)
blosozumab (INN)
Bluboro bluensomycin (INN) BMS 337039 BMS-232632
boceprevir (USAN...
-
romosozumab (targets sclerostin, by Amgen),
fresolimumab (TGF-β, Sanofi),
blosozumab (sclerostin, Lilly), and
setrusumab (sclerostin,
begun by Novartis). Setrusumab...
-
lymphoblastic leukemia (ALL) (CD19+)
Blontuvetmab Blontress mab
veterinary CD20
Blosozumab mab
humanized SOST
osteoporosis Bococizumab mab
humanized PCSK9 dyslipidemia...
- (February 2015). "A randomized, double-blind
phase 2
clinical trial of
blosozumab, a
sclerostin antibody, in
postmenopausal women with low bone mineral...
